Skip to content
The Policy VaultThe Policy Vault

KuvanCareFirst (Caremark)

Dihydropteridine reductase (DHPR) deficiency

Initial criteria

  • Member is age ≥ 1 month
  • Diagnosis confirmed for one of the listed biopterin metabolic defects
  • Medication prescribed by or in consultation with a physician who specializes in the treatment of metabolic disease and/or PKU

Reauthorization criteria

  • Member experiencing benefit from therapy as evidenced by disease stability or improvement

Approval duration

Initial 6 months; reauthorization 6 months